These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

780 related items for PubMed ID: 33707134

  • 21. Medication-related osteonecrosis of the lower jaw without osteolysis on computed tomography images.
    Kojima Y, Sawada S, Sakamoto Y.
    J Bone Miner Metab; 2024 Jan; 42(1):27-36. PubMed ID: 38194089
    [Abstract] [Full Text] [Related]

  • 22. Infection and medication-related osteonecrosis of the jaw.
    Katsarelis H, Shah NP, Dhariwal DK, Pazianas M.
    J Dent Res; 2015 Apr; 94(4):534-9. PubMed ID: 25710950
    [Abstract] [Full Text] [Related]

  • 23. Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts.
    Zhao N, Li QX, Wang YF, Qiao Q, Huang HY, Guo CB, Guo YX.
    BMC Oral Health; 2023 May 27; 23(1):330. PubMed ID: 37245004
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Further development of the MRONJ minipig large animal model.
    Otto S, Pautke C, Martin Jurado O, Nehrbass D, Stoddart MJ, Ehrenfeld M, Zeiter S.
    J Craniomaxillofac Surg; 2017 Sep 27; 45(9):1503-1514. PubMed ID: 28803745
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Quantitative assessment of mandibular bone marrow using computed tomography texture analysis for detect stage 0 medication-related osteonecrosis of the jaw.
    Ito K, Muraoka H, Hirahara N, Sawada E, Hirohata S, Otsuka K, Okada S, Kaneda T.
    Eur J Radiol; 2021 Dec 27; 145():110030. PubMed ID: 34798536
    [Abstract] [Full Text] [Related]

  • 31. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA, Liang STY, Sax AZ, Wu K, Yom SK, Huryn JM, Estilo CL.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May 27; 125(5):440-445. PubMed ID: 29580668
    [Abstract] [Full Text] [Related]

  • 32. Analysis of medication-related osteonecrosis of the jaw with bone SPECT/CT: relationship between patient characteristics and maximum standardized uptake value.
    Ogawa R, Ogura I.
    Dentomaxillofac Radiol; 2021 Dec 01; 50(8):20200516. PubMed ID: 34019434
    [Abstract] [Full Text] [Related]

  • 33. Preventive effect of fluvastatin on the development of medication-related osteonecrosis of the jaw.
    Adachi N, Ayukawa Y, Yasunami N, Furuhashi A, Imai M, Sanda K, Atsuta I, Koyano K.
    Sci Rep; 2020 Mar 27; 10(1):5620. PubMed ID: 32221325
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
    Kawahara M, Kuroshima S, Sawase T.
    Int J Implant Dent; 2021 May 14; 7(1):47. PubMed ID: 33987769
    [Abstract] [Full Text] [Related]

  • 36. The Prevention of Medication-related Osteonecrosis of the Jaw.
    Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P.
    Dtsch Arztebl Int; 2017 Feb 03; 114(5):63-69. PubMed ID: 28241916
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.
    Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, Takenobu T, Hashida T.
    Support Care Cancer; 2022 Mar 03; 30(3):2341-2348. PubMed ID: 34738163
    [Abstract] [Full Text] [Related]

  • 39. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V, Campisi G, Bedogni A.
    Support Care Cancer; 2022 Sep 03; 30(9):7047-7051. PubMed ID: 35312858
    [Abstract] [Full Text] [Related]

  • 40. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.
    Roato I, Mauceri R, Notaro V, Genova T, Fusco V, Mussano F.
    Int J Mol Sci; 2023 Apr 27; 24(9):. PubMed ID: 37175652
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.